huADB22D Frozen Validation Report
343 PRS models · 1,636 protein predictions · 137 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Body composition with favourable glucose handling
near-term focus
Your strongest metabolic pattern is not simple diabetes risk. The evidence leans toward easier weight or central-fat gain, while glucose, insulin, cholesterol, and diabetes-related signals look relatively favourable.
Full explanation
The clearest metabolic theme is a split pattern. Several inherited signals point toward higher body weight, waist size, visceral fat, and obesity tendency.
At the same time, the glucose side looks more protective than expected from the body-composition side. Signals related to diabetes, long-term blood sugar, glucose, insulin resistance, high cholesterol, and favourable cholesterol balance all lean in a better direction.
That means the useful interpretation is not that genetics says diabetes is likely. It is that body composition may deserve attention even when glucose handling is genetically less concerning.
This is worth discussing or reviewing if waist size, weight trend, blood pressure, cholesterol, blood sugar, liver enzymes, urate, energy, appetite, or family history make the body-composition side more relevant in real life.
What to watch forUse waist trend, weight trend, blood pressure, lipids, blood sugar, liver enzymes, and urate as the real-world anchors; focus habits on sustainable fat loss or waist control if those markers begin moving the wrong way.
Show technical evidence
Risk-score evidence
- weight: risk percentile 95.1%, coverage 96%, PGS003898.
- waist circumference: risk percentile 89.7%, coverage 99%, PGS000827.
- predicted visceral adipose tissue: risk percentile 90.7%, coverage 97%, PGS000844.
- obesity: risk percentile 88.3%, coverage 96%, PGS003959.
- fasting proinsulin: risk percentile 87.6%, coverage 95%, PGS000840.
- incident type 2 diabetes: risk percentile 0.3%, coverage 99%, PGS002779.
Protein pathway context
- SERPINA12: predicted level percentile 9.1%, R2 0.5774; pathway context only.
- C1QTNF9: predicted level percentile 15.6%, R2 0.5406; pathway context only.
Candidate variants
- PCSK5 rs11144688 GG: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- Variant rs11160190 GG: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
Heart rhythm, valve and circulation background
useful to review
There are meaningful heart and circulation signals, especially around rhythm, valve, stroke, and heart-structure context, but favourable coronary and cholesterol signals keep the category mixed.
Full explanation
The cardiovascular evidence is mixed rather than one-directional. Rhythm, valve, stroke, general circulation, and heart-structure signals are present enough to deserve a card.
The counterweight is important. Several inherited signals related to coronary disease, heart attack, chronic ischaemic heart disease, and high cholesterol lean in a favourable direction, and favourable cholesterol context appears in the metabolic evidence too.
This points to awareness rather than a genetic verdict. The practical value is in knowing that rhythm, valve, blood-pressure, exercise-tolerance, and circulation context may be more informative than cholesterol alone.
This is worth discussing or reviewing if there are palpitations, fainting, chest pressure, unusual breathlessness, reduced exercise tolerance, high blood pressure, abnormal cholesterol, a heart murmur, stroke-like symptoms, or a close family history of early heart disease or rhythm problems.
What to watch forKeep routine cardiovascular basics current, and use symptoms such as palpitations, fainting, chest pressure, breathlessness, exercise drop-off, or high blood pressure as reasons to review this category with a clinician.
Show technical evidence
Risk-score evidence
- atrial fibrillation and flutter: risk percentile 87.2%, coverage 100%, PGS001841.
- left ventricular mass index: risk percentile 81.5%, coverage 100%, PGS003427.
- stroke: risk percentile 81.2%, coverage 100%, PGS004124.
- circulatory disease nec: risk percentile 92%, coverage 100%, PGS001847.
- coronary artery disease: risk percentile 10.7%, coverage 98%, PGS000058.
- myocardial infarction: risk percentile 6.1%, coverage 87%, PGS001316.
Protein pathway context
- PDGFRB: predicted level percentile 7.1%, R2 0.5601; pathway context only.
- CFHR4: predicted level percentile 88.1%, R2 0.6355; pathway context only.
- SERPINA12: predicted level percentile 9.1%, R2 0.5774; pathway context only.
- ABO: predicted level percentile 81%, R2 0.6423; pathway context only.
Candidate variants
- Variant rs10503669 CC: snpedia_context.
Sleep, snoring and airway resilience
useful to review
Sleep duration, snoring, dozing, and lung-function evidence cluster together. The category is mixed because some respiratory signals are favourable while others suggest airway or sleep vulnerability.
Full explanation
A sleep-airway pattern shows up in the evidence. Signals related to sleep duration, snoring, daytime dozing, waking pattern, and lower respiratory infection sit close to lung-function signals.
This does not mean there is a sleep disorder or lung disease. It means sleep quality, airway mechanics, and breathing efficiency may be a useful lens, especially because body composition can interact with snoring and daytime energy.
The respiratory side is not purely adverse. Some lung-function and airway-obstruction signals lean more favourable, so this is best treated as a mixed resilience category.
This is worth discussing or reviewing if there is loud snoring, witnessed pauses in breathing, waking unrefreshed, morning headaches, persistent daytime sleepiness, unexplained exercise limitation, chronic cough, wheeze, or repeated lower-airway infections.
What to watch forTreat sleep quality and breathing as performance signals: review this if snoring, daytime sleepiness, morning headaches, reduced exercise capacity, cough, or wheeze become noticeable.
Show technical evidence
Risk-score evidence
- sleep duration: risk percentile 97.4%, coverage 100%, PGS001978.
- snoring: risk percentile 97.1%, coverage 100%, PGS002006.
- daytime dozing sleeping: risk percentile 81.8%, coverage 100%, PGS001995.
- sleeplessness insomnia: risk percentile 0.2%, coverage 100%, PGS001932.
- pef pred ratio: risk percentile 96.5%, coverage 93%, PGS001010.
- lung function: risk percentile 91.9%, coverage 93%, PGS001237.
Protein pathway context
- SFTPD: predicted level percentile 81.7%, R2 0.5378; pathway context only.
- TLR3: predicted level percentile 3.9%, R2 0.8019; pathway context only.
- CLEC7A: predicted level percentile 90.5%, R2 0.5374; pathway context only.
Digestive, liver and medication-processing context
useful to review
Digestive-system, liver-enzyme, fatty-liver, gallbladder, duodenitis, and malabsorption signals are one of the clearer body-system clusters. Drug-response findings add practical prescribing context.
Full explanation
The digestive and liver evidence is broad enough to stand on its own. Signals include digestive-system growth context, total protein, liver-enzyme elevation, nonalcoholic liver disease, duodenitis, gallstones, and intestinal malabsorption.
This does not diagnose a liver, gallbladder, bowel, or absorption problem. It does suggest that digestive symptoms, liver blood tests, gallbladder symptoms, and medication choices could be more informative than average.
Drug-response genetics also belongs here, but not as a standalone main card. It matters if medicines such as some acid-suppressing drugs, antidepressants, clopidogrel, tacrolimus, hydralazine, or efavirenz are ever being considered.
This is worth discussing or reviewing if there are persistent abdominal symptoms, right-upper-abdominal pain after fatty meals, unexplained nausea, pale stools, jaundice, abnormal liver enzymes, malabsorption symptoms, medication side effects, or a need to choose one of the affected medicines.
What to watch forUse real symptoms, liver enzymes, gallbladder symptoms, digestion changes, and medication decisions as the triggers; share the drug-response findings before starting affected prescriptions.
Show technical evidence
Risk-score evidence
- benign neoplasm of other parts of digestive system: risk percentile 99.9%, coverage 100%, PGS001812.
- total protein: risk percentile 99.9%, coverage 100%, PGS002001.
- chronic elevation of alanine aminotransferase: risk percentile 91.9%, coverage 96%, PGS002732.
- other chronic nonalcoholic liver disease: risk percentile 91.4%, coverage 100%, PGS001860.
- duodenitis: risk percentile 88.4%, coverage 100%, PGS001852.
- cholelithiasis: risk percentile 88.1%, coverage 92%, PGS001174.
Protein pathway context
- FUCA1: predicted level percentile 91.4%, R2 0.822; pathway context only.
- MAN2B2: predicted level percentile 91.1%, R2 0.599; pathway context only.
- GC: predicted level percentile 17.8%, R2 0.6763; pathway context only.
Candidate variants
- UGT1A6,UGT1A7,UGT1A8,UGT1A9,UGT1A10 rs1105879 AA: snpedia_context.
- Variant rs11117432 GG: snpedia_context.
- MYNN rs10936599 TT: snpedia_context.
- SLC9A4 rs1014286 AA: snpedia_context.
Medication-response context
- CYP2C19: Rapid Metabolizer, *1/*17; affected medicines include Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole.
- NAT2: Poor Metabolizer, *16/*30; affected medicines include hydralazine.
- CYP2B6: Intermediate Metabolizer, *1/*9; affected medicines include Efavirenz, Bupropion, Methadone.
- CYP3A5: Poor Metabolizer, *3/*3; affected medicines include Tacrolimus, Sirolimus.
- ABCG2: Decreased Function, rs2231142 reference (G)/rs2231142 variant (T); affected medicines include See CPIC guidance.
Immune signalling and inflammatory balance
useful to review
Immune evidence is prominent, especially from genetically predicted immune proteins. The direction is mixed: some inflammatory and immune-cell signals are high, while several allergic and autoimmune traits are favourable.
Full explanation
The immune system is one of the richest evidence lanes in this profile. Many genetically predicted proteins involved in immune-cell signalling, immune receptors, complement, and inflammatory control are in the tails.
The inherited trait evidence is not one-way. Sarcoidosis and several immune-cell count signals appear on the risk-skewed side, but eczema, psoriasis, rheumatoid arthritis, and nasal-polyp context lean more favourable.
This is best read as immune-response style rather than a diagnosis. It may describe how immune signalling is genetically tuned, not whether a specific immune disease is present.
This is worth discussing or reviewing if there are persistent unexplained inflammatory symptoms, recurrent unusual infections, prolonged fevers, swollen glands, unexplained rashes, breathing symptoms with inflammation, autoimmune family history, or abnormal inflammatory blood tests.
What to watch forKeep this as immune-response context; review it if persistent inflammation, unusual infections, unexplained rashes, autoimmune family history, or abnormal inflammatory labs make it relevant.
Show technical evidence
Risk-score evidence
- sarcoidosis: risk percentile 98.9%, coverage 100%, PGS001872.
- basophil count: risk percentile 96.8%, coverage 84%, PGS000163.
- eosinophil percentage: risk percentile 91.7%, coverage 96%, PGS003944.
- monocyte count: risk percentile 89.8%, coverage 100%, PGS001968.
- hayfever allergic rhinitis: risk percentile 95.8%, coverage 87%, PGS001259.
- atopic eczema or atopic disease: risk percentile 2%, coverage 98%, PGS003459.
Protein pathway context
- FCGR2A: predicted level percentile 99.7%, R2 0.5811; pathway context only.
- FOLR3: predicted level percentile 0.4%, R2 0.9226; pathway context only.
- LCP1: predicted level percentile 98.7%, R2 0.5128; pathway context only.
- CCL24: predicted level percentile 1.4%, R2 0.7115; pathway context only.
- CD200R1: predicted level percentile 98.6%, R2 0.5497; pathway context only.
- CD300LF: predicted level percentile 97.6%, R2 0.5333; pathway context only.
Candidate variants
- Variant rs10865331 GG: snpedia_context.
- LOC105369984 rs10774624 GG: snpedia_context.
- Variant rs11117432 GG: snpedia_context.
Kidney, urate and fluid-balance context
useful to review
Kidney and fluid-related evidence is mixed. Urate, gout, urine-albumin, filtration, calcium, water-intake, and stone-context signals appear, while chronic-kidney and creatinine/cystatin context is favourable.
Full explanation
A kidney-fluid-mineral cluster appears across the evidence. It includes filtration, urine albumin, urate, gout, calcium, water intake, urinary-stone context, creatinine, cystatin, sodium, and urea signals.
The direction is mixed. Urate and gout are more risk-skewed, and urine-albumin context is worth noting, but chronic-kidney-disease and several kidney-marker signals lean in a favourable direction.
The most practical interpretation is hydration, blood pressure, urate, kidney markers, and mineral balance rather than a genetic diagnosis of kidney disease.
This is worth discussing or reviewing if there is gout, kidney-stone history, high uric acid, high blood pressure, swelling, abnormal urine protein, abnormal kidney blood tests, dehydration-prone training, or a family history of kidney disease.
What to watch forAnchor this category to urate, blood pressure, urine protein, kidney markers, hydration demands, and any stone or gout history rather than assuming current kidney disease.
Show technical evidence
Risk-score evidence
- egfr: risk percentile 97.7%, coverage 100%, PGS004005.
- urine albumin to creatinine ratio: risk percentile 80.5%, coverage 98%, PGS000861.
- chronic kidney disease: risk percentile 6.9%, coverage 100%, PGS004128.
- cystatin c mg l: risk percentile 7.2%, coverage 93%, PGS000680.
- creatinine: risk percentile 8%, coverage 100%, PGS001945.
- urinary calculus: risk percentile 12.5%, coverage 100%, PGS001864.
Protein pathway context
- LCP1: predicted level percentile 98.7%, R2 0.5128; pathway context only.
- CFHR4: predicted level percentile 88.1%, R2 0.6355; pathway context only.
Joint loading, cartilage and urate background
useful to review
Joint and connective-tissue evidence is meaningful, especially osteoarthritis, knee arthrosis, other joint conditions, urate, gout, and cartilage-pathway context.
Full explanation
The musculoskeletal evidence points toward joints and connective tissue more than muscle performance alone. Osteoarthritis, knee arthrosis, other joint conditions, fibroblastic context, urate, and gout signals appear together.
This category also connects back to body composition. Higher body-size and central-fat tendencies can increase mechanical load, while urate and gout context can affect joints through a different pathway.
Protein-pathway context around cartilage and tissue structure adds support, but it is not a measured joint test and does not say joint disease is present.
This is worth discussing or reviewing if there is persistent joint pain, swelling, reduced range of motion, recurrent tendon or connective-tissue issues, gout-like flares, high uric acid, knee symptoms, or training limitations that do not match conditioning.
What to watch forPrioritize joint-resilient strength work and review this category if joint pain, swelling, gout-like flares, high uric acid, or training limitations show up.
Show technical evidence
Risk-score evidence
- osteoarthritis: risk percentile 92.9%, coverage 89%, PGS001290.
- other arthropathies: risk percentile 92.9%, coverage 100%, PGS001877.
- gonarthrosis arthrosis of knee: risk percentile 84.5%, coverage 90%, PGS001192.
- gout: risk percentile 84.1%, coverage 100%, PGS004006.
- serum urate: risk percentile 81.5%, coverage 99%, PGS000126.
- fibroblastic disorders: risk percentile 80.6%, coverage 82%, PGS001031.
Protein pathway context
- CRTAC1: predicted level percentile 3%, R2 0.5057; pathway context only.
- TNN: predicted level percentile 90%, R2 0.5604; pathway context only.
- MMP3: predicted level percentile 82.8%, R2 0.5052; pathway context only.
Candidate variants
- Variant rs10865331 GG: snpedia_context.
Blood-cell and iron-trait context
background
Blood-cell size, reticulocyte, platelet-volume, haemoglobin-related, and iron-status signals form a real trait cluster. This is context, not a diagnosis of anaemia or a blood disorder.
Full explanation
Several inherited signals relate to blood-cell traits. These include red-cell size, haemoglobin-related measures, reticulocyte measures, platelet volume, red-cell count, haematocrit, and iron-status context.
The direction is mixed because some measures are high and others are low or protective. That pattern is common in trait genetics and does not imply that current blood counts are abnormal.
The value is that routine blood-count results may be easier to interpret with this background, especially if several values are high-normal, low-normal, or persistently unusual.
This is worth discussing or reviewing if there is unexplained fatigue, breathlessness, paleness, dizziness, bruising, bleeding, abnormal iron studies, abnormal blood counts, or a family history of blood-cell disorders.
What to watch forUse routine blood-count and iron-study results as the anchor; review this category if fatigue, breathlessness, bruising, bleeding, abnormal counts, or abnormal iron markers appear.
Show technical evidence
Risk-score evidence
- mean corpuscular hemoglobin: risk percentile 98.1%, coverage 100%, PGS001989.
- mean corpuscular volume: risk percentile 96.4%, coverage 100%, PGS001990.
- mean reticulocyte volume: risk percentile 95.1%, coverage 100%, PGS002003.
- high light scatter reticulocyte percentage: risk percentile 92.6%, coverage 96%, PGS003951.
- mean plateletvolume: risk percentile 88.5%, coverage 96%, PGS003934.
- red blood cellcount: risk percentile 3.8%, coverage 96%, PGS003925.
Protein pathway context
- ABO: predicted level percentile 81%, R2 0.6423; pathway context only.
Candidate variants
- RCL1 rs10758658 GG: snpedia_context.
- ATP2B4 rs10900585 TT: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
Brain wiring, mood and habit context
background
Brain-region research context, mood, headache, smoking, cannabis, and habit-related evidence appear together. Protective mental-health and addiction-related signals keep this as background awareness.
Full explanation
The brain and behaviour category is mostly context. It includes headache, depression-related, smoking-initiation, time-to-first-cigarette, cannabis-use, habit, and brain-region research signals.
The protective side matters. Several signals related to post-traumatic stress, loneliness, recent depression, probable depression, attention-related traits, addiction context, and fluid intelligence lean more favourable or protective.
The brain-region evidence is research background, not a medical-risk conclusion. It can support a richer picture of brain wiring but should not be read as a diagnosis or prediction of symptoms.
This is worth discussing or reviewing if there are persistent low mood, anxiety, headaches, attention problems, substance-use concerns, sleep disruption affecting mood, strong family history, or a noticeable change in cognition, motivation, or behaviour.
What to watch forUse this as context for mood, headache, sleep, and habit patterns; review it if symptoms, substance-use concerns, family history, or noticeable cognitive or mood changes make it relevant.
Show technical evidence
Risk-score evidence
- lifetime major depressive disorder: risk percentile 84.1%, coverage 98%, PGS000139.
- post traumatic stress disorder: risk percentile 1.4%, coverage 100%, PGS005393.
- loneliness: risk percentile 1.5%, coverage 86%, PGS001091.
- attention deficit hyperactivity disorder: risk percentile 15.2%, coverage 100%, PGS003753.
- addiction risk factors: risk percentile 7.7%, coverage 100%, PGS005215.
- volume of caudate: risk percentile 96.4%, coverage 89%, PGS001543.
Protein pathway context
- DBH: predicted level percentile 82.9%, R2 0.6647; pathway context only.
- ADGRB3: predicted level percentile 87%, R2 0.597; pathway context only.
- ACP6: predicted level percentile 98.1%, R2 0.6207; pathway context only.
Skin, sun, eyes and hearing background
background
Skin-growth, childhood-sunburn, eye-pressure, retinal, corneal, glasses, hearing, and appearance signals appear together. Protective skin-cancer context adds nuance.
Full explanation
This is a sensory and appearance-background category. It includes skin-growth and sunburn-related signals, as well as eye-pressure, retinal, corneal, glasses, hearing, and visible-ageing context.
The skin-cancer side is not risk-skewed. Several skin-cancer-related signals lean favourable, so the point is not that genetics predicts skin cancer.
The more useful angle is awareness: sun response, benign skin changes, eye pressure or retina context, and hearing changes may be worth treating as ordinary care items rather than ignoring.
This is worth discussing or reviewing if there are changing skin lesions, repeated severe sunburn, unusual skin growths, vision changes, known high eye pressure, retinal findings, new hearing difficulty, or strong family history of eye, hearing, or skin disease.
What to watch forKeep routine skin, eye, and hearing care proportionate to real findings; review this category if changing skin lesions, eye-pressure concerns, retinal findings, or new hearing difficulty appear.
Show technical evidence
Risk-score evidence
- seborrheic keratosis: risk percentile 93.6%, coverage 88%, PGS001140.
- childhood sunburn: risk percentile 84.4%, coverage 87%, PGS001257.
- non melanoma skin cancer: risk percentile 5.7%, coverage 89%, PGS001040.
- basal cell carcinoma: risk percentile 19.2%, coverage 100%, PGS003416.
- corneal resistance factor: risk percentile 88.7%, coverage 91%, PGS001383.
- intraocular pressure: risk percentile 81.1%, coverage 93%, PGS000879.
Candidate variants
- TAS2R38 rs10246939 TT: snpedia_context; Phenylthiocarbamide tasting.
- TYR rs1042602 CC: snpedia_context; Albinism or congenital nystagmus · Oculocutaneous albinism · SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN · Oculocutaneous albinism type 1B · Oculocutaneous albinism type 1A.
- CDKN2B rs1063192 AA: common_variant_context; Three Vessel Coronary Disease · Malignant tumor of breast.
Prostate and male reproductive background
background
Male reproductive and prostate-related evidence is mostly favourable, with prostate-pathway proteins and a prostate-cancer context variant keeping it useful as background.
Full explanation
For a male profile, prostate and reproductive evidence is worth separating from general cancer context. Signals related to enlarged prostate, prostate hyperplasia, male genital tract cancer, testicular cancer, testosterone, and number of self-reported cancers lean mostly favourable.
Protein-pathway evidence related to prostate and reproductive biology adds background. This does not mean prostate disease or fertility issues are present.
A prostate-cancer context variant appears, but it should be treated as context rather than a diagnosis, especially because the broader inherited score evidence is more protective-skewed.
This is worth discussing or reviewing if urinary symptoms, pelvic symptoms, fertility concerns, abnormal prostate screening, testicular changes, hormone symptoms, or a close family history of prostate or testicular cancer make it relevant.
What to watch forTreat this as reassuring background, but review it if urinary symptoms, abnormal prostate screening, testicular changes, hormone symptoms, fertility concerns, or close family history appear.
Show technical evidence
Risk-score evidence
- hyperplasia of prostate: risk percentile 3.4%, coverage 80%, PGS001338.
- enlarged prostate: risk percentile 17.2%, coverage 71%, PGS001015.
- male genital tract cancer: risk percentile 4.7%, coverage 69%, PGS001111.
- testosterone nmol l: risk percentile 17.1%, coverage 93%, PGS000696.
- number of self reported cancers: risk percentile 17.3%, coverage 88%, PGS001005.
Protein pathway context
- PSCA: predicted level percentile 2.3%, R2 0.7849; pathway context only.
- MSMB: predicted level percentile 87.9%, R2 0.5861; pathway context only.
- KLK3: predicted level percentile 20%, R2 0.6695; pathway context only.
- INSL3: predicted level percentile 85.6%, R2 0.7312; pathway context only.
- CRISP2: predicted level percentile 8.2%, R2 0.5552; pathway context only.
- ZP3: predicted level percentile 92.4%, R2 0.7546; pathway context only.
Candidate variants
- Variant rs10505483 CC: snpedia_context.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C19
RAPID METABOLIZER
*1/*17
Affected drugs: Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
CYP2B6
INTERMEDIATE METABOLIZER
*1/*9
Affected drugs: Efavirenz, Bupropion, Methadone
NAT2
POOR METABOLIZER
*16/*30
Affected drugs: hydralazine
ABCG2
DECREASED FUNCTION
rs2231142 reference (G)/rs2231142 variant (T)
Affected drugs: See CPIC guidance
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.